ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2975

Journal of Clinical & Experimental Pathology received 2975 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

HuR (ELAV1) as a potential tumor marker in gastroesophageal junction adenocarcinoma

Joint Event on 15th International Congress on American Pathology and Oncology Research & International Conference on Microbial Genetics and Molecular Microbiology

Wenyi Luo, Tongfeng Tan and Erin Rubin

Anderson Cancer Center, USAUniversity of Oklahoma Health Sciences Center, USA

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C5-058

Abstract
HuR is a master protein involved in the regulation of mRNA stability. Increased HuR expression and cytoplasmic translocation in tumors are associated with poor prognoses and altered responses to chemotherapy. HuR expression has been studied in esophageal squamous cell carcinoma, but not in gastroesophageal junction (GEJ) adenocarcinoma arising in Barrett's esophagus. To study HuR, formalin fixed paraffin embedded tissue blocks of twenty patients who underwent endoscopic mucosal resection for GEJ adenocarcinoma without pre-operative neoadjuvant therapy and five patients with Barrett's esophagus without dysplasia were retrieved upon approval of Institutional Review Board. Tissue blocks were sectioned and stained with 1:500 diluted mouse monoclonal anti-Human HuR antibody clone HuR-Rb SC-5261 (Santa Cruz, CA) and a horseradish peroxidase-conjugated secondary antibody with a Leica BOND-III automated IHC/ISH-stainer. The cytoplasmic and nuclear staining patterns of HuR were evaluated separately and scored. The intensity and cytoplasmic localization of HuR staining correlate with the neoplastic potential of the lesion. HuR staining is only detected in nuclei of benign metaplastic columnar mucosa (nuclear AIRS:2.3; cytoplasmic AIRS: 0). Barrett’s epithelium shows stronger nuclear staining (AIRS:6.0) and some cytoplasmic staining (AIRS:5.2). Adenocarcinomas including poorly-differentiated adenocarcinoma and adenocarcinoma with mucinous differentiation show markedly increased HuR staining in both nuclei (AIRS:9.4) and cytoplasm (AIRS:9.4). In specimens with Barrett’s epithelium and dysplasia, HuR expression appears higher in the latter. This study provides a potential novel diagnostic and differential diagnostic marker of esophageal glandular neoplasms and may also provide a novel therapeutic opportunity.
Biography

E-mail: luowenyi2008@hotmail.com

 

Top